This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Following the success of Issue 3 , which focused on the critical importance of patient diversity in clinicalresearch, Xtalks is thrilled to announce Xtalks Clinical Edge Issue 4. These prominent leaders will share their experiences, strategies and visions about whats next for clinicalresearch.
Real-world evidence (RWE) is emerging as an important area of research to reveal, in real time, new insights and innovations and is accelerating the development of new and innovative therapies and treatments to improve patient outcomes. The webinar will also cover: The challenges of RWE research and how they are being overcome.
The Indian life sciences sector is making strides by integrating quantum computing, artificial intelligence (AI), machine learning (ML), advanced analytics, bigdata, internet of things (IoT) and blockchain into their research and development efforts.
Real-world evidence (RWE) is emerging as an important area of research to reveal, in real time, new insights and innovations in medicine. But, until recently, an important data source has been locked up in the electronic health record (EHR), often in the form of unstructured or ‘free’ text entered by healthcare professionals.
If you hadn’t already noticed, the clinicalresearch enterprise has well and truly entered the era of “bigdata,” artificial intelligence (AI), and machine learning. It also includes search and support services that help patients understand, find, and enroll in clinical trials.”
In a few weeks, the EU-funded research project Darwin EU will announce its first batch of data partners for the ambitious real-world data -driven Horizon 2020 project. A major objective of this project hinges on exploiting national EHR data to complete observational studies quicker than industry standards.
Pérez-Stable, MD, Director of the National Institute on Minority Health and Health Disparities (NIMHD), shared his thoughts on national priorities for reducing health disparities and opportunities for clinicalresearchers to help promote health equity. He recommended sitting down with people as equals to co-develop research.
We know that the demand at the site level for studies is growing and the workforce capacity is shrinking, notes Bree Burks, RN, MSN, Vice President of Strategy for Veeva Systems, who will present on The ClinicalResearch Technology Reboot: Are We Getting it Right? The ClinicalResearch Technology Reboot: Are We Getting it Right?
Just in time to help recognize Pride Month , ACRP’s ClinicalResearcher journal is pleased to share the first details from the lead peer-reviewed article on “Improving Cardiovascular Research for Transgender and Gender Diverse Populations” from a trio of WCG IRB expert contributors to the new issue going online today (June 13).
Landry is a professor of medicine and epidemiology at Oxford Population Health and deputy director of the University of Oxford’s BigData Institute. ElZarrad is the director of the Office of Medical Policy in the FDA’s Center for Drug Evaluation and Research.
Just in time to help recognize Pride Month , ACRP’s ClinicalResearcher journal is pleased to share the first details from the lead peer-reviewed article on “Improving Cardiovascular Research for Transgender and Gender Diverse Populations” from a trio of WCG IRB expert contributors to the new issue going online today (June 13).
Just in time to help recognize Pride Month , ACRP’s ClinicalResearcher journal is pleased to share the first details from the lead peer-reviewed article on “Improving Cardiovascular Research for Transgender and Gender Diverse Populations” from a trio of WCG IRB expert contributors to the new issue going online today (June 13).
With more healthcare facilities transitioning from paper charts to electronic records and electronic health records (EHRs) becoming more integrated and technologically advanced, EHRs are expected to drive big changes in the provision of healthcare and clinicalresearch delivery.
Alphabet subsidiary and precision health company Verily recently announced a breakthrough in its AI drug discovery GPCR research collaboration with Sosei Heptares. The companies hope that in the year to come those data targets will be entered for validation, hit generation, and lead selection.
Some of the medical advances with the technology are genomics and epigenetics, BigData, AI and ML which are allowing molecular […] Technology adoptions like artificial intelligence and machine learning are bringing in major transformation in the way a primary physician will extend treatment protocols.
Real-world evidence (RWE) is emerging as an important area of research to reveal, in real time, new insights and innovations and is accelerating the development of new and innovative therapies and treatments to improve patient outcomes.
Attendees will learn more about how an SCA was used at the design and execution phases in a recent study of new treatments for relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL) and will also receive an eBook ‘How to harness the potential of AI and real-world data for clinicalresearch’. About the panel.
Here at CDS, we’ve long envisioned the mobile app as an end-to-end solution, encapsulating integral functions from electronic patient-reported outcomes (ePRO) and electronic data capture (EDC) to clinical trial management system (CTMS) and randomization and trial supply management (RTSM). More accurate data.
Clinical trials are prospective biomedical research studies designed to evaluate medical, surgical or behavioral interventions in people and investigate novel approaches for the diagnosis and prevention / treatment of diseases. Clinicalresearch can be classified into two types: observational studies and clinical trials.
Through these collaborations, advanced technologies tied to AI and bigdata are being employed to develop personalized and targeted medicines, ultimately leading to more effective treatments for diseases like cancer and immune deficiencies,” Lyons notes.
And this is where modern technologies and data-driven medical informatics can really bridge the gaps in rare disease research,” said Dr Joanne Hackett, head of Genomic and Precision Medicine at IQVIA, during a recent pharmaphorum webinar. Navigating rare disease research and treatment.
The big headline out of the health care M&A world today is Swiss pharmaceutical giant Roche’s $1.9 billion acquisition of Flatiron Health, the Alphabet-backed, cancer-focused digital health analytics upstart that’s attempting to use real world patient information and bigdata to spur better oncology R&D.
The big headline out of the health care M&A world today is Swiss pharmaceutical giant Roche’s $1.9 billion acquisition of Flatiron Health, the Alphabet-backed, cancer-focused digital health analytics upstart that’s attempting to use real world patient information and bigdata to spur better oncology R&D.
The Wall Street Journal has an interesting article on the use of “BigData” to identify and solicit potential clinical trial participants. The premise is that large consumer data aggregators like Experian can target patients with certain diseases through correlations with non-health behavior.
Following its most recent financing round , Massive Bio’s trial enrollment platform has been evolving into a command center to supply research stakeholders with real-time communications, data, and enhanced analytics. These patients can be anywhere waiting to get access to a clinical trial. Co-founder and CEO of Massive Bio.
Rise of the machines – bigdata, AI and machine learning. Companies will capitalise on tech advances in the areas of data use to inform R&D and/or provide personalised care to patients. Patients are beginning to expect the providers of their medicines to help them with their condition and the impact on their lives.
As we explore Genmab’s strategic vision, technological advancements and the next frontier in antibody research, we gain insights into the future of medicine — a future where Genmab’s cutting-edge therapies are poised to transform patient care and meet the complex challenges of the next generation of healthcare.
For this research, we identified 164 relevant solutions and picked 5 to showcase below. These companies were chosen based on a data-driven startup scouting approach, taking into account factors such as location, founding year, and technology among others. Heat Map: 5 Top Pharmacovigilance Startups.
Companies wishing to take part in the pilot can contact the EMA here, and those selected will be able to file their applications, including raw data from September of this year.
Although approach differs slightly amongst organizations in clinicalresearch, everyone agrees on this: it’s time for the industry to become more agile. Too many life-saving treatments and medical advancements are at stake to remain attached to the traditional ways of data collection.
International deep real-world evidence company Savana is on a mission to give health researchers the power to unlock the clinical value embedded within electronic health records (EHRs) using artificial intelligence (AI) and clinical Natural Language Processing (NLP) techniques. AI use in the pandemic.
This is a relatively new model of clinical trials in terms of adoption and is, therefore, the highly underutilized method of conducting clinicalresearch. Undoubtedly, virtual clinical trials leverage the power of tele-health/digital technology by including virtual patient monitoring, wearable medical devices, remote SDV, etc.
Meanwhile, decentralisation and the BigData revolution are transforming the way researchers run clinical trials, and previously untapped geographies are emerging as new hubs for future research. Clinical trials management is no exception.
There has never been a time when rapid, low burden access to patient-level data, at scale, was more urgent.
rows of data. Syntegra has also engaged with the Federal Drug Administration (FDA) to evaluate the role of synthetic data in regulatory decisions, for COVID-19 and beyond.
.
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content